Bydureon and Injection site mass - a phase IV clinical study of FDA data

Summary:

We study 24,077 people who have side effects when taking Bydureon. Injection site mass is found, especially among people who are female, 60+ old, have been taking the drug for 1 - 6 months, also take Metformin and have High blood cholesterol.

The phase IV clinical study analyzes which people take Bydureon and have Injection site mass. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 30, 2023

24,077 people reported to have side effects when taking Bydureon.
Among them, 2,752 people (11.43%) have Injection site mass.

What is Bydureon?

Bydureon has active ingredients of exenatide synthetic. It is used in type 2 diabetes. Currently, eHealthMe is studying from 24,157 Bydureon users.

What is Injection site mass?

Injection site mass is found to be associated with 1,255 drugs and 746 conditions by eHealthMe. Currently, we are studying 34,616 people who have Injection site mass.

Number of Bydureon and Injection site mass reports submitted per year:

Could Bydureon cause Injection site mass?

* Approximation only. Some reports may have incomplete information.

Do you take Bydureon and have Injection site mass?

Check whether Injection site mass is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Bydureon side effects by duration, gender and age:

Bydureon side effects (24,157 reports)

Injection site mass treatments and more:

Injection site mass (34,616 reports)

Common drugs associated with Injection site mass:

All the drugs that are associated with Injection site mass:

Injection site mass (1,255 drugs)

Common conditions associated with Injection site mass:

Type 2 diabetes: 3,658 reports
Multiple sclerosis: 3,191 reports
Rheumatoid arthritis: 2,849 reports
High blood cholesterol: 1,488 reports
Diabetes: 1,402 reports

All the conditions that are associated with Injection site mass:

Injection site mass (746 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on exenatide synthetic (the active ingredients of Bydureon) and Bydureon (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.